Artelo Biosciences, INC. (ARTL) — 10-Q Filings

10-Q Filings (6)

• ARTL's Losses Widen Amid Soaring R&D, G&A Costs — Nov 12, 2025 Risk: high
  ARTELO BIOSCIENCES, INC. (ARTL) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $8,713,000, up from $6,048,00
• ARTL's Losses Widen Amid Increased R&D, Aggressive Financing Moves — Aug 13, 2025 Risk: high
  ARTELO BIOSCIENCES, INC. (ARTL) reported a net loss of $3,221 thousand for the three months ended June 30, 2025, an increase from $2,433 thousand in the prior y
• Artelo Biosciences Q1 2025: Minimal Revenue, Balanced Assets/Liabilities — May 13, 2025 Risk: high
  Artelo Biosciences, Inc. filed its Q1 2025 10-Q report on May 13, 2025, for the period ending March 31, 2025. The company reported minimal revenue, with $0.001
• Artelo Biosciences Reports Minimal Revenue in Q3 2024 — Nov 12, 2024 Risk: high
  Artelo Biosciences, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported minimal revenue, with $0.001 million in revenue for the n
• Artelo Biosciences Reports Q2 2024 Results — Aug 13, 2024 Risk: high
  Artelo Biosciences, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported minimal revenue, with total revenues for the six months ended
• Artelo Biosciences, Inc. Files 10-Q for Period Ending March 31, 2024 — May 13, 2024 Risk: low
  ARTELO BIOSCIENCES, INC. (ARTL) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Artelo Biosciences, Inc. reported financial results for the quarte

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX